Abbott reports third-quarter results on Wednesday

Abbott Laboratories is scheduled to report its third-quarter results on Wednesday, 21 October 2026, before the market opens, according to earnings calendar data.

The consensus estimate calls for adjusted earnings of 1.43 USD per share and revenue of 13.12 billion USD for the third quarter of 2026. Zacks Investment Research also compiled consensus estimates of 1.43 USD in adjusted earnings per share and 12.91 billion USD in net sales. Abbott's official guidance range for third-quarter adjusted diluted earnings per share stands between 1.38 USD and 1.46 USD. Over the last four quarters, Abbott exceeded expectations once and trailed estimates three times, with surprises ranging from negative 1.1% to positive 1.4%.

On 7 October 2026, Abbott launched Ensure Max Protein 3-in-1 Muscle Support, which combines 30 grams of protein, 5 grams of creatine, and 3 grams of calcium HMB. On 5 October 2026, the US Food and Drug Administration cleared new patient-facing capabilities for the CardioMEMS HF System, enabling heart failure patients to monitor pressure readings via a mobile application.

On 30 September 2026, Abbott reported that its SimpleScreen CRC blood test recorded an overall clinical sensitivity of 81.1% for colorectal cancer detection in the PREEMPT CRC study. Earlier in September, Abbott announced an exclusive partnership with Berry Street on 23 September to pair its over-the-counter Lingo biowearable with virtual nutrition coaching.

On 17 September 2026, Abbott declared a quarterly common dividend of 63 cents per share, payable on 16 November 2026. On 15 September 2026, the company announced the first commercial use in Canada of its Volt Pulsed Field Ablation System to treat atrial fibrillation. On 14 September 2026, Abbott agreed to pay 385 million USD to settle US Department of Justice and state lawsuits tied to the 2022 recall of infant formula manufactured in Sturgis, Michigan.